Related Experiment Videos

Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma

P Ragazzini1, G Gamberi, M S Benassi

  • 1Laboratory of Oncologic Research, Rizzoli Orthopedic Institute, Bologna, Italy.

Insights

Gene alterations in chromosome 12, including SAS, CDK4, and MDM2, are implicated in low-grade osteosarcoma. This study found SAS amplification and MDM2/CDK4 protein expression in tumor samples, suggesting their role in osteosarcoma development.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • The 12q13-15 chromosomal region harbors SAS, CDK4, and MDM2 genes.
  • These genes are frequently altered in various human sarcomas.

Purpose of the Study:

  • To evaluate SAS gene amplification and MDM2/CDK4 protein expression in central low-grade osteosarcoma.
  • To investigate the potential role of these genetic alterations in osteosarcoma tumorigenesis and progression.

Main Methods:

  • Analysis of 20 central low-grade osteosarcoma samples (16 primary, 3 recurrent, 1 lung metastasis).
  • Quantitative polymerase chain reaction (PCR) for SAS gene amplification.
  • Immunohistochemistry for MDM2 and CDK4 protein expression on paraffin-embedded tissues.

Main Results:

  • MDM2 protein overexpression observed in 35% of samples.
  • CDK4 protein overexpression observed in 65% of samples.
  • SAS gene amplification detected in 15% of samples.

Conclusions:

  • MDM2 and CDK4 protein overexpression and SAS amplification are present in a subset of low-grade osteosarcomas.
  • These genetic and protein alterations may contribute to the development and progression of low-grade osteosarcoma.

Related Concept Videos